Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prograf vs Neoral in Hispanic Kidney Transplant Recipients
NCT00983645Phase 4
Key facts
- Status
- Terminated
- Start
- Oct 2004
- Primary completion
- Oct 2012
- Countries
- 1
- Sponsor
- Loma Linda University
- Modality
- Peptides, Orthosteric Ligands
- Conditions
- kidney transplant rejection
01
Overview
Phase 4, randomised, open-label trial of tacrolimus + Wuzhi capsule and cyclosporine in kidney transplant rejection (2 arms), sponsored by Loma Linda University. Primary endpoint: Rejection at 6 months. Started Oct 2004; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Neoral
Cyclosporine (Neoral) starting dose 3mg/kg PO BID
Prograf
Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
03
Who it enrols
Adult Hispanic patients receiving a primary cadaveric or living donor kidney transplant, excluding those with prior transplants, multi-organ transplants, history of diabetes mellitus, PRA > 20%, or cold ischemia time > 24 hours.
04
Endpoints
Primary
Rejection
Secondary
Renal Function
Post-transplant Diabetes Mellitus
Lipid Levels
Beyond the preview
Go deeper on NCT00983645.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00983645.